Systemic corticosteroids are not effective for symptom control in patients with acute rhinosinusitis.
Subcutaneous dupilumab significantly reduced the use of oral corticosteroids in patients with corticosteroid-dependent severe asthma.
Compared to the control group, patients who took four or more oral corticosteroid prescriptions had 1.29 times the odds of experiencing a new adverse effect within the year.
Patients with asthma are at higher risk of pulmonary embolism, particularly if the asthma is severe or they take oral corticosteroids.
Drugs in the Pipeline
Treatment with masitinib, a selective tyrosine kinase inhibitor, significantly reduces the rate of severe asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids, according to data from a phase 3 study.
Highest rates of adverse events seen within first month after initiating short course of oral steroids.
Treatment with mepolizumab was associated with a significant reduction in asthma exacerbations and oral corticosteroid use in patients with severe eosinophilic asthma.
In the asthma clinical trials, the most common adverse reactions were injection site reactions, oropharyngeal pain, and eosinophilia.
Peak expiratory flow increases were greater with benralizumab than placebo in patients with severe eosinophilic asthma.
Patients with both asthma and allergies had a significant increase in the number of prescriptions dispensed for controller medications.